Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Brandão, Leonardo R., Albisetti, Manuela, Halton, Jacqueline, Bomgaars, Lisa, Chalmers, Elizabeth, Mitchell, Lesley G., Nurmeev, Ildar, Svirin, Pavel, Kuhn, Tomas, Zapletal, Ondrej, Tartakovsky, Igor, Simetzberger, Monika, Huang, Fenglei, Sun, Zhichao, Kreuzer, Jörg, Gropper, Savion, Brueckmann, Martina, Luciani, Matteo
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019192/
https://ncbi.nlm.nih.gov/pubmed/31805182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000998
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados